You are here: Industry Insights > ALS

News List

BrainStorm Announces Financial Results for the Third Quarter of 2020 and Provides a Corporate Update prnewswire
October 16, 2020
BrainStorm Cell Therapeutics Inc., a leading developer of cellular therapies for neurodegenerative diseases, announced financial results for the third quarter ended September 30, 2020, and provided a corporate update.
Global ALS market may grow to $1.04 bn in 2029 driven by anticipated drug launches expresspharma
October 09, 2020
A GlobalData report also informs that there are major unmet needs in the ALS market, such as finding curative drugs, receiving earlier diagnosis, identifying reliable biomarkers and extending patient survival.
Immunity Pharma Announces Promising Interim Results of Study with IPL344 in ALS americanpharmaceuticalreview
September 22, 2020
Immunity Pharma announced interim results from its Phase 1/2a clinical study with IPL344, an Akt activating disease-modifying drug for the treatment of ALS.
NeuroSense Announces Encouraging Interim Results of Clinical Study in ALS americanpharmaceuticalreview
September 17, 2020
NeuroSense Therapeutics, a Biotech company developing PrimeC, a combination drug which aims to slow ALS progression, announced PrimeC was safe and well tolerated in the interim analysis of study NST002, a Phase IIa study conducted by ...
Project ALS Granted FDA Orphan Drug Designation for Prosetin americanpharmaceuticalreview
September 17, 2020
Project ALS announced the Food and Drug Administration (FDA) has granted orphan drug designation to prosetin for the treatment of ALS. Prosetin is an oral, brain penetrant MAP4 kinase inhibitor developed by scientists at Columbia University for the ...
Promising interim results from ALS study testing IPL344 europeanpharmaceuticalreview
September 16, 2020
The data suggests disease deterioration was halved in the six Amyotrophic Lateral Sclerosis (ALS) patients treated with IPL344 over eight months.
AZTherapies Doses First Patient in ALZT-OP1a Study for ALS americanpharmaceuticalreview
September 16, 2020
AZTherapies announced the dosing of the first patient in its Phase 2a clinical trial examining the safety and efficacy of ALZT-OP1a in patients with mild- to moderate-stage Amyotrophic Lateral Sclerosis (ALS).
Seelos Receives FDA May Proceed Notice to Initiate a Trial of SLS-005 in ALS americanpharmaceuticalreview
August 14, 2020
Seelos Therapeutics received notice from the Food and Drug Administration (FDA) that the company may proceed with initiating a Phase IIb/III trial studying SLS-005 (trehalose) for the treatment of Amyotrophic lateral sclerosis ...
Kadimastem Reports Positive Interim Results of ALS AstroRx Trial americanpharmaceuticalreview
August 10, 2020
Kadimastem announced its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company's Phase 1/2a clinical trial in ALS.
Experimental motor neurone disease therapy shows promise europeanpharmaceuticalreview
July 15, 2020
Tofersen reduced expression of the SOD1 gene known to cause amyotrophic lateral sclerosis (ALS) and slowed clinical decline in the Phase I/II trial.

Previous page 1 2 3 4 5 6 7 8 Next page